Hagaajinta cusub ee tilmaamaha ku saabsan dawooyinka opioid-ka ee xanuunka joogtada ah
Published
Tilmaamaha S3 ee isticmaalka muddada dheer ee opioid-ka xanuunka joogtada ah ee aan sababta kansarka ahayn, oo loo yaqaan LONTS, waa la cusboonaysiiyay. Tilmaamahan wuxuu siinayaa dhakhaatiirta talooyin ku saabsan sida ay u qori karaan daawooyin xanuun-baabi'iye xoogga leh muddo dheer. Tilmaamaha S3 waa heerka ugu sarreeya ee tilmaamaha caafimaadka ee Jarmalka.
Xanuunka joogtada ah wuxuu socdaa in ka badan saddex ilaa lix bilood, oo badanaa sababtiisa si cad uma xiriirto cudur sida kansarka. Opioid-ku waa daawooyin xanuun-baabi'iye xoogga leh oo lagu isticmaali karo xanuunadaas. Isla markaana way kuu sameyn karaan ku-tiirsanaan iyo saamaynta dhinac ahaan. Sidaas darteed waa muhiim in daaweynta si taxaddar leh loo qorsheeyo oo si joogto ah loo eego.
Tilmaamaha la hagaajiyay waxay ujeedadiisu tahay inay dhakhaatiirta ka caawiso inay qorista daawooyinkaas ku waafajiyaan aqoonta caafimaad ee hadda jirta. Taas waxaa ka mid ah doorashada dawooyinka, go'aaminta cabbirka, iyo kormeerka joogtada ah ee natiijada daaweynta. Iskaashiga dhakhaatiirta guriga, dhakhaatiirta takhasuska leh iyo khubarada xanuunka ayaa sidoo kale door muhiim ah ka ciyaara.
Bukaannada Jarmalka ku nool ee xanuunka joogtada ah qabta, cusboonaysiintu waxay ugu horeysa micnaheedu yahay in daaweyntooda loo sameeyo heerarka khibrada ee midka ah. Qof kasta oo su'aalo ka qabo daaweynta xanuunkiisa wuxuu la xiriiri karaa dhakhaatirkiisa ama dhakhaatiirta daaweynta haya.
Sources: Ärzte Zeitung
More Germany news
- Real estate fund buys third business park near Munich
- Large battery storage planned in Germany: 500 megawatts and 2,000 megawatt-hours
- SAP takes over AI company TechWolf
- Climate activists Camille Étienne and Luisa Neubauer to discuss in Berlin
- Five European countries plan deportations to Rwanda
- Truist Securities keeps buy recommendation for Ardent Health
- Safe-Space-Apotheken und Marktplatz der Gesundheit: What is behind them?
- Regis Healthcare: Transcript of call with shareholders and analysts published